Global Cancer Biomarkers Market Is Likely To Grow At A CAGR Value Of Around 16.90% By 2028

27-Apr-2022 | Zion Market Research

The global Cancer Biomarkers market was worth around USD 12,419.50 million in 2021 and is estimated to grow to about USD 31695.03 million by 2028, with a compound annual growth rate (CAGR) of approximately 16.90 percent over the forecast period. The report analyzes the Cancer Biomarkers market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Cancer Biomarkers market.

Cancer is the world's second leading cause of death, according to the World Health Organisation (WHO). Biomarkers are chemical, physical, or biological parameters that can be used to diagnose disease. Oncology biomarkers enable rapid, non-invasive cancer diagnosis while also improving cancer detection and screening. Furthermore, the rising prevalence of several lifestyle disorders is expected to drive the market, as biomarkers play an important role in risk assessment, early diagnosis, and effective treatment monitoring. Owing to the rise in demand of Cancer Biomarkers, the global Cancer Biomarkers market is estimated to grow at a CAGR of 16.90% during the forecast period.

Certain factors driving market growth include increased cancer incidence worldwide and higher acceptance of cancer treatments in developing regions, a paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis, and increased use of biomarkers in drug development. Rising patient and healthcare professional awareness of the importance of early cancer detection, as well as rising demand for personalised medicine, are expected to provide this cancer biomarker market with significant growth opportunities in the coming decade. Diagnostic biomarkers for early diagnosis allow doctors to choose better treatment options, resulting in a successful recovery in less time.

The global Cancer Biomarkers market is segregated based on biomarkers type, cancer type, profiling technologies and application. Based on biomarkers type, the global Cancer Biomarkers market is distinguished into Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers. The protein biomarkers segment dominates the market. Based on cancer type, the Cancer Biomarkers market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukaemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer and Other Cancer Types. The breast cancer segment is expected to lead over the forecast period. Based on profiling technologies, the Cancer Biomarkers market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics and Cytogenetics. The omics technologies segment is expected to dominate the market. Based on application, the cancer biomarkers market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment and Other Applications. The diagnostics applications is expected to dominate the market.

Global Cancer Biomarkers Market

North America led the regional segment, closely followed by Europe. The presence of key pharmaceutical companies, established R&D infrastructure pertaining to the development of novel diagnostic products, and increased demand for specific & early diagnostics are the major factors contributing to the aforementioned dominance.

However, the Asia Pacific region is expected to experience a profitable CAGR over the forecast period due to rising cancer prevalence, a favourable environment for clinical trials, and increased government funding for drug development programmes. Furthermore, the growing focus of pharmaceutical companies on this region, combined with rising awareness of biomarker-based diagnosis, is one of the high impact-rendering growth drivers.

Key players functioning in the global Cancer Biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.      (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

Browse the full Cancer Biomarkers Market By Biomarkers Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer and Other Cancer Types), By Profiling Technologies (Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics and Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessment and Other Applications) and By Region – Global Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2022 – 2028.” Report at

Recents Developments

  • In March 2021, Roche announced that the VENTANA ALK (D5F3) CDx Assay has been approved as a companion diagnostic by the US Food and Drug Administration. This assay test is the only one approved by the FDA as a companion diagnostic for LORBRENA, and it will aid in quickly identifying patients with this cancer biomarker so that they can receive more effective treatment.
  • In July 2020, Thermo Fisher Scientific has announced the signing of a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., as well as an application to the Ministry of Health, Labour, and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients in Japan who are candidates for entrectinib.

???????Global Cancer Biomarkers market is segmented as follows:

By Biomarkers Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Leukemia
  • Thyroid Cancer
  • Bladder Cancer
  • Non-Hodgkin's Lymphoma
  • Kidney Cancer
  • Other Cancer Types

By Profiling Technologies

  • Omics Technologies
  • Imaging Technologies
  • Immunoassay
  • Bioinformatics
  • Cytogenetics

By Application

  • Diagnostics
  • Research & Development
  • Prognostics
  • Risk Assessment
  • Other Applications

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed